Case definitions and diagnostic criteria for myalgic encephalomyelitis and chronic fatigue syndrome: From clinical-consensus to evidence-based case definitions

Neuroendocrinology Letters

Volumn 34, Issue 3, 2013, Pages 185-199

  Morris, Gerwyn ^a   Maes, Michael ^b,c  

^a Deakin University ^*

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Autoimmune; Chronic fatigue syndrome; Cytokines; Inflammation; Myalgic encephalomyelitis; Neuro immune; Oxidative and nitrosative stress

Indexed keywords

BIOLOGICAL MARKER;

CHRONIC FATIGUE SYNDROME; COGNITION; CONSENSUS; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EMPIRICAL RESEARCH; EPIDEMIC; EVIDENCE BASED MEDICINE; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATTERN RECOGNITION; PRACTICE GUIDELINE; REVIEW; SCIENTIST; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYMPTOM; VALIDATION STUDY;

EID: 84878954435     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M et al. (2007). Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 78: 36-42. (Pubitemid 46048261)
2. Aarsland D, Marsh L, Schrag A (2009). Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 24: 2175-2186.
3. Acheson D (1959). The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med. 26: 569-595.
4. Ashcraft MH (2002) Math Anxiety: Personal, educational, and cognitive consequences. Curr Direct Psychol Sci. 11: 5181-5185.
5. Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR (1998). High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging. 8: 228-234. (Pubitemid 28457989)
6. Barnden LR, Crouch B, Kwiatek R, Burnet R, Mernone A, Chryssidis S et al. (2011). A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. 24: 1302-1312.
7. Bassi N, Amital D, Amital H, Doria A, Shoenfeld Y (2008). Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis. Isr Med Assoc J. 10: 79-82. (Pubitemid 351649474)
8. Befroy DE, Shullman GI (2011). Magnetic resonance spectroscopy studies of human metabolism. Diabetes. 60: 1361-1369.
9. Bianchi MC, Tosetti M, Battini R, Manca ML, Mancuso M, Cioni G et al. (2003). Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. AJNR Am. J. Neuroradiol. 24: 1958-1966. (Pubitemid 37444845)
10. Blei ML, Conley KE, Kushmerick MJ (1993). Separate measures of ATP utilization and recovery in human skeletal muscle. J Physiol. 465: 203-222. (Pubitemid 23201393)
11. Booth, NE, Myhill S, McLaren-Howard J (2012). Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med. 5: 208-220.
12. Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W (2004). Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 75: 246-249. (Pubitemid 38183532)
13. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J et al. (2011). Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med. 9: 81.
14. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J et al. (2012). Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 10: 88.
15. Broderick G (2012). Response to 'A controversial consensus'; by the International Consensus Panel. J Intern Med. 271: 213-217.
16. Brooks JC, Roberts N, Whitehouse G, Majeed T (2000). Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol. 73: 1206-1208.
17. Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW et al. (2001). In vivo visualization of activated glia by (11C) (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. 124: 2014-2027. (Pubitemid 32945901)
18. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM et al. (2003). Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: clinical working case definition, diagnostic and treatment protocols. J Chr Fatig Syndr. 11: 7-36.
19. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T et al. (2011). Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 270: 327-338.
20. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. (1993). Development of a fatigue scale. J Psychosom Res. 37: 147-153. (Pubitemid 23128452)
21. Chaudhuri A, Condon B, Gow J, Brennan D, Hadley D (2003). Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. Brain Imaging. 14: 225-228. (Pubitemid 36308415)
22. Cho HJ, Wessely S (2005). Chronic fatigue syndrome: an overview. Rev Bras Psiquiatr. 27: 174-175. (Pubitemid 41337478)
23. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC et al. (2006). Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med. 47: 215-222. (Pubitemid 46780885)
24. David AS (1991). Postviral syndrome and psychiatry. Br Med Bull. 47: 966-988.
25. De Becker P, McGregor N, De Meirleir K (2001). A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome. J Intern Med. 250: 234-240. (Pubitemid 34205691)
26. Detre JA, Wang ZY, Bogdan AR, Gusnard DA, Bay CA, Bingham PM et al. (1991). Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol. 29: 218-221.
27. Diaz-Olavarrieta C, Cummings JL, Velazquez J, Garcia de la Cadena C (1999). Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin. Neurosci. 11: 51-57. (Pubitemid 29070664)
28. Ellenberger H (1970). The Discovery of the Unconscious. New York, Basic Books.
29. Ellenberger HF (1972). The story of "Anna O": a critical review with new data. J Hist Behav Sci. 8: 267-279.
30. Eva KW (2003). The influence of the differentially processing evidence on diagnostic decision making. Dissertation Abstracts International: Section B: The Sciences and Engineering. 63: 4393.
31. Figved N, Klevan G, Myhr KM, Glad S, Nyland H, Larsen JP et al. (2005). Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand. 112: 463-468. (Pubitemid 41676691)
32. Friedberg F, Jason LA (2002). Selecting a fatigue rating scale. The CFS Research Review. 35: 7-11.
33. Friedlander M, Phillips S (1984). Preventing Anchoring Errors in Clinical Judgment. Journal of Consulting and Clinical Psychology. 52: 366-371.
34. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 121: 953-959. (Pubitemid 24370860)
35. Garb H (1998). Studying the Clinician: Judgment research and Psychological Assessment. American Psychological Association. Washington D.C.
36. Garrabou G, Sanjurjo E, Miro O, Martinez E, Infante AB, Lopez S et al. (2006). Noninvasive diagnosis of mitochondrial dysfunction in HAART-related hyperlactatemia. Clin Infect Dis. 42: 584-585. (Pubitemid 43202544)
37. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ (2006). In vivo imaging of microglial activation with (11C)(R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 21: 89-93. (Pubitemid 43273758)
38. Goudsmit EM, Stouten B, Howes S (2008). Fatigue in Myalgic Encephalomyelitis. Bulletin of IACFS/ME. 16: 4-10.
39. Goudsmit E, Shepherd C, Dancey CP, Howes S (2009). ME: Chronic fatigue syndrome or a distinct clinical entity? Health Psychology Update. 18: 26-31.
40. Hannestad J, Gallezot JD, Schafbauer T, Lim K, Kloczynski T, Morris ED et al. (2012). Endotoxin-induced systemic in!ammation activates microglia: (11C)PBR28 positron emission tomography in nonhuman primates. NeuroImage. 63: 232-239.
41. Haverkamp B (1993). Confirmatory Bias in Hypothesis Testing for Client- Identified and Counselor Self- Generated Hypotheses. J. Couns Psychol. 40: 303-315.
42. Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW et al. (2004). Imaging of activated microglia with PET and (11C) PK 11195 in corticobasal degeneration. Mov Disord. 19: 817-821. (Pubitemid 39139594)
43. Hirschmuller A (1978). The life and work of Josef Breuer: physiology and psychoanalysis. New York: New York University Press.
44. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE et al. (1988). Chronic fatigue syndrome: a working case definition. Ann Intern Med. 108: 387-389.
45. Hooper M (2011). Initial response by Professor Malcolm Hooper to an undated letter sent by Professor Peter White to Dr Richard Horton, Editor-in-Chief of The Lancet. http://www.meactionuk.org.uk/Hoopers-initial- response-to-PDW-letter.htm (Accessed 19 November 2012).
46. Jason LA, Richman JA, Friedberg F, Wagner L, Taylor R, Jordan KM (1997a). Politics, science, and the emergence of a new disease. The case of chronic fatigue syndrome. Am Psychol. 52: 973-983. (Pubitemid 127681371)
47. Jason LA, Ropacki MT, Santoro NB, Richman JA, Heatherly W, Taylor R et al. (1997b). A screening scale for chronic fatigue syndrome: Reliability and validity. JCFS. 3: 39-59. (Pubitemid 27074983)
48. Jason LA, Torres-Harding SR, Carrico AW, Taylor RR (2002). Symptom occurrence in persons with chronic fatigue syndrome. Biol Psychol. 59: 15-27. (Pubitemid 34084798)
49. Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S (2008). The economic impact of ME/CFS: individual and societal costs. Dyn Med. 7: 6.
50. Jason LA, Evans M, Brown A, Brown M, Porter N, Hunnell J et al. (2010). Sensitivity and Specificity of the CDC Empirical Chronic Fatigue Syndrome Case Definition. Psychology. 1: 9-16.
51. Jason LA, Evans M, Brown M, Porter N, Brown A, Hunnell J et al. (2011). Fatigue Scales and Chronic Fatigue Syndrome: Issues of Sensitivity and Specificity. Disabil Stud Q. 31: DOI: pii: 1375.
52. Jason LA, Brown A, Clyne E, Bartgis L, Evans M, Brown M (2012). Contrasting case definitions for chronic fatigue syndrome, Myalgic Encephalomyelitis/chronic fatigue syndrome and myalgic encephalomyelitis. Eval Health Prof. 35: 280-304.
53. Jung WI, Staubert A, Widmaier S, Hoess T, Bunse M, van Erckelens F et al. (1997). Phosphorus J-coupling constants of ATP in human brain. Magn Reson Med. 37: 802-804. (Pubitemid 27187822)
54. Kaptchuk TJ (2003). Effect of interpretive bias on research evidence. BMJ. 326: 1453-1455.
55. Lloyd AR (1998). Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. Am J Med. 105(3A): 7S-10S.
56. Maes M (2011). An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry. 35: 784-794.
57. Maes M, Leunis JC (2008). Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett. 29: 902-910.
58. Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990). Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology. 24: 115-120.
59. Maes M, Mihaylova I, Leunis JC (2006). Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett. 27: 615-621. (Pubitemid 46050019)
60. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009). Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis / chronic fatigue syndrome. Neuro Endocrinol Lett. 30: 715-722.
61. Maes M, Twisk FN, Johnson C (2012a). Myalgic Encephalomyelitis (ME), Chronic Fatigue Syndrome (CFS), and Chronic Fatigue (CF) are distinguished accurately: Results of supervised learning techniques applied on clinical and inflammatory data. Psychiatry Res. 200: 754-760.
62. Maes M, Twisk FN, Ringel K (2012b). Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom. 81: 286-295.
63. Maes M, Twisk FNM, Kubera M, Ringel K (2012c). Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J Affect Disord. 136: 933-939.
64. Maes M, Twisk FN, Kubera M, Ringel K, Leunis JC, Geffard M (2012d). Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord. 136: 909-917.
65. Maes M, Anderson G, Morris G, Berk M (2013) Editorial: Diagnosis of Myalgic Encephalomyelitis: where are we now? Expert Opin Med Diagn. doi:10.1517/17530059.2013.776039.
66. Matsuda J, Gohchi K, Gotch N (1994). Serum concentrations of 2′,5′-oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression. J Neurol Neurosurg Psychiatry. 57: 1015-1016. (Pubitemid 24251085)
67. Meulemans A, Gerlo E, Seneca S, Lissens W, Smet J, Van Coster R et al. (2007). The aerobic forearm exercise test, a non-invasive tool to screen for mitochondrial disorders. Acta Neurol Belg. 107: 78-83. (Pubitemid 350104255)
68. Mihaylova I, DeRuyter M, Rummens JL, Bosmans E, Maes M (2007). Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett. 28: 477-483. (Pubitemid 47577730)
69. Mintzopoulos D, Mindrinos MN, Rahme LG, Tompkins RG, Tzika AA (2009). 31P NMR demonstrates reduced ATP synthesis rate and concomitant downregulation of PGC-1β mitochondrial gene expression in skeletal muscle after burn injury. Proc Intl Soc Mag Reson Med. 17: 1914.
70. Morriss R, Wearden AJ, Mullis R (1998). Exploring the validity of the Chalder fatigue scale in chronic fatigue syndrome. J Psychosom Res. 45: 411-417. (Pubitemid 28499986)
71. Morris G, Maes M (2012a). A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab Brain Dis. 2012 (Epub ahead of Print).
72. Morris G, Maes M (2012b). Increased nuclear factor-κB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses. 79: 607-613.
73. Mosconi L (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 32: 486-510.
74. Murr C, Widner B, Wirleitner B, Fuchs D (2002). Neopterin as a marker for immune system activation. Curr. Drug. Metab. 3(2): 175-187. (Pubitemid 34326529)
75. Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P et al. (2010). Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 23: 643-650.
76. Myhill S, Booth NE, McLaren-Howard J (2009). Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2: 1-16.
77. Mynatt CR, Doherty ME, Tweney RD (1977). Confirmation bias in a simulated research environment: An experimental study of scientific inference. Quart J Exp Psychol. 29: 85-95.
78. National Task Force (1994). Report from National Task Force on Chronic Fatigue Syndrome (CFS) Post Viral Fatigue Syndrome (PVFS) Myalgic Encephalomyelitis (ME). Bristol: Westcare. September 1994, p15.
79. Nunez M, Fernandez-Sola J, Nunez E, Fernandez-Huerta JM, Godas-Sieso T, Gomez-Gil E (2011). Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up. Clin Rheumatol. 30: 381-389.
80. Oskamp S (1965). Overconfidence in Case-Study Judgments. J Consult Psychol. 29: 261-265.
81. Price RK, North CS, Wessely S, Fraser VJ (1992). Estimating the prevalence of chronic fatigue syndrome and associated symptoms in the community. Public Health Rep. 107: 514-522.
82. Prinster A, Quarantelli M, Lanzillo R, Orefice G, Vacca G, Carotenuto B et al. (2010). A voxel-based morphometry study of disease severity correlates in relapsing - remitting multiple sclerosis. Mult Scler. 16: 45-54.
83. Puri BK, Counsell SJ, Zaman R, Main J, Collins AG, Hajnal JV et al. (2002). Relative increase in choline in the occipital cortex in chronic fatigue syndrome. Acta Psychiatr Scand. 106: 224-226.
84. Ramsay M (1981). Myalgic encephalomyelitis: a baffling syndrome. Nurs Mirror. 153: 40-41.
85. Ramsay AM (1986). Postviral Fatigue Syndrome: The Saga of Royal Free Disease. London: Gower Medical. ISBN-10: 0906923964.
86. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G et al. (2003). International Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res. 3: 25.
87. Reeves WC, Wagner D, Nisenbaum R, Jones JF, Gurbaxani B, Solomon L et al. (2005). Chronic fatigue syndrome - a clinically empirical approach to its definition and study. BMC Med. 3: 19.
88. Ridsdale L, Hurley M, King M, McCrone P, Donaldson N (2012). The effect of counselling, graded exercise and usual care for people with chronic fatigue in primary care: a randomized trial. Psychol Med. 42: 2217-2224.
89. Scheinbaum BW (1979). Psychiatric Diagnostic Error. Schizophrenia Bulletin. 5: 560-563.
90. Schmitz JPJ, van Riel NAW, Jeneson JAL, Nicolaij K, Hilbers PAJ (2008). A multi-scale model of human skeletal muscle: extracting metabolite dynamics at cellular scale from measurements at whole organ. International Conference on Systems Biology, Gothenburg, Germany.
91. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A et al. (1991). A report-chronic fatigue syndrome: guidelines for research. J R Soc Med. 84: 118-121.
92. Shephard RJ (2003). Limits to the measurement of habitual physical activity by questionnaires. Br J Sports Med. 37: 197-206.
93. Siessmeier T, Nix W, Hardt J, Schreckenberger M, Egle U, Bartenstein P (2003). Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 74: 922-928. (Pubitemid 36782997)
94. Silverman B (1992). Modeling and Critiquing the Confirmation Bias in Human Reasoning. IEEE. Transactions on Systems, Man, and Cybernetics. 22: 972-982.
95. Slater E (1965). Diagnosis of "Hysteria". Br Med J. 1: 1395-1399.
96. Slater E (1982). What is Hysteria? Roy A (Ed.), Hysteria, pp 40.
97. Smets EM, Garssen B, Bonke B, De Haes JC (1995). The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 39: 315-325.
98. Sonawane A, Jyot J, During R, Ramphal R (2006). Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa. Infect Immun. 74: 6682-6689. (Pubitemid 44913142)
99. Stouten B (2005). Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res. 5: 37.
100. Streit WJ, Mrak RE, Griffin WST (2004). Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation. 1: 14.
101. Sulloway FJ (1991). Reassessing Freud's case histories: the social construction of psychoanalysis. Isis. 82: 245-275.
102. Taivassalo T, Abbott A, Wyrick P, Haller RG (2002). Venous oxygen levels during aerobic forearm exercise: An index of impaired oxidative metabolism in mitochondrial myopathy. Ann Neurol. 51: 38-44. (Pubitemid 34027975)
103. Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG (2003). The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain. 126: 413-423. (Pubitemid 36172745)
104. Tarnopolsky M (2004). Exercise testing as a diagnostic entity in mitochondrial myopathies. Mitochondrion. 4: 529-542.
105. Thone J, Kessler E (2008). Improvement of neuropsychiatric symptoms in multiple sclerosis subsequent to high-dose corticosteroid treatment. Prim Care Companion J. Clin. Psychiatry. 10(2): 163-164. (Pubitemid 351872810)
106. Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J (2000). Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity. 12: 201-210. (Pubitemid 30398634)
107. Tolpin M (1993). The unmirrored self, compensatory structure, and cure: the exemplary case of Anna O. Freud's Case Studies: Self-Psychological Perspectives. Magid B (Ed.), Hillsdale, NJ, The Analytic Press, Annual of Psychoanalysis. 21: 157-177.
108. Tversky A, Kahneman D (2004). Judgment Under Uncertainty: Heuristics and Biases. Science. 185: 1124-1131.
109. Twisk FN, Maes M (2009). A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME) / chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett. 30: 284-299.
110. Urenjak J, Williams SR, Gadian DG, Noble M (1993). Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 13: 981-989. (Pubitemid 23067586)
111. van Adel BA, Tarnopolsky MA (2009). Metabolic Myopathies: Update 2009. J Clin Neuromusc Dis. 10: 97-121.
112. van der Meer JWM, Lloyd AR (2012). A controversial consensus - comment on article by Broderick et al. J Int Med. 271: 29-31.
113. VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR (2010). Postexertional malaise in women with Chronic Fatigue Syndrome. J Womens Health. 19: 239-244.
114. Van Oosterwijck J, Nijs J, Meeus M, Lefever I, Huybrechts L, Lambrecht L et al. (2010). Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome; an experimental study. J Intern Med. 268: 265-278.
115. Vermeulen RCW, Kurt RM, Visser FC, Sluiter W, Scholte HR (2010). Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med. 8: 93.
116. Wagner D, Nisenbaum R, Heim C, Jones JF, Unger ER, Reeves WC (2005). Psychometric properties of the CDC Symptom Inventory for assessment of chronic fatigue syndrome. Popul Health Metr. 3: 8.
117. Ware JE, Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). Medical Care. 30: 473-483.
118. Ware JE, Snow KK, Kosinski M (2000). SF-36 Health Survey: Manual and Interpretation Guide. Quality Metric Incorporated. Lincoln RI.
119. Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S et al. (2010). Fatigue Intervention by Nurses Evaluation (FINE) trial writing group and the FINE trial group. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial. BMJ. 340: 1777.
120. Wessely S (1990). Chronic Fatigue and Myalgia Syndromes. Psychological Disorders in General Medical Settings. Sartorius N, Goldberg D, de Girolamo G, et al. (Eds.). Hogrefe & Huber. pp 82-97.
121. Wessely S (1995). The epidemiology of chronic fatigue syndrome. Epidemiol Rev. 17: 139-151.
122. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D (1997). The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Public Health. 87: 1449-1455. (Pubitemid 27415000)
123. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC et al. (2011). PACE trial management group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 377: 823-836.
124. Whitwell JL (2009). Voxel-Based Morphometry: An Automated Technique for Assessing Structural Changes in the Brain. J Neurosci. 29: 9661-9664.
125. Wood JM, Nezworski MT, Lilienfeld SO, Garb HN (2003). What's wrong with the Rorschach? Science confronts the controversial inkblot test. San Francisco: Jossey-Bass.
126. Wu F, Jeneson JA, Beard DA (2007). Oxidative ATP synthesis in skeletal muscle is controlled by substrate feedback. Am J Physiol Cell Physiol 292: C115-C124. (Pubitemid 46115125)